

ADMINISTRATIVE SANCTIONS IMPOSED BY CONSOB IN CONNECTION WITH THE ALLEGED BREACH TO DISCLOSE OBLIGATIONS RELATING TO INSIDE INFORMATION. ACTION FOR ANNULMENT

Saluggia, June 5, 2023 – DiaSorin informs that the Italian National Commission for Companies and the Stock Exchange (CONSOB) has imposed an administrative fine against the Company for an amount of Euro 100,000 claiming the violation of the disclosure obligations provided for by Article 17, section 1, of the “MAR Regulation” and that today, on the basis of the same assumptions on the alleged unlawful communication of inside information resulted in the administrative sanction imposed to the Company, CONSOB has also sanctioned its Chief Executive Officer Mr. Carlo Rosa, as better indicated below.

The sanction imposed against the Company relates to the information disclosed to the market through the press releases disseminated by DiaSorin on March 10, 2020 and April 7, 2020, regarding the completion of studies for the launch, respectively, of a molecular test and of a serological test, for the diagnosis and identification of the immune response to SARS-CoV-2, information that – in CONSOB’s opinion – would have had to be qualified by the Company as inside information.

In this respect, the Company, among others, points out that in the relevant period its behaviour was consistent with its past practice, since the development of new products was never managed as inside information. Moreover, the behaviour of the Company is in line with that held by all the other diagnostic companies in the European market which are required to comply with the MAR Regulation; in particular, also such companies did not qualify as inside information the one relating to the launch of diagnostic tests for COVID-19 contained in the press releases that they had disseminated during the same period.

CONSOB, moving from the same allegations, more specifically those relating to the studies concerning the launch of the serological test, today imposed to Mr. Carlo Rosa, in connection to the supposed unlawful communication of inside information, an administrative fine of Euro 20,000 and the mandatory accessory administrative sanction – consisting in the temporary disqualification from holding administration, management and control offices of listed companies – for a period of two months.

In any event, it is worth noting that Mr. Carlo Rosa has not been charged for the purchase or sale of DiaSorin shares nor for any unlawful, direct or indirect, activity or solicitation whatsoever with regards to the Company's securities.

The Company has already appealed the relevant administrative sanction and Mr. Carlo Rosa will promptly appeal, before the competent Court of Appeal of Milan, the sanction imposed to him in order to obtain the annulment. The appeal in the interest of Mr. Carlo Rosa will also include the request for immediate suspension of the effectiveness of the disqualifying accessory administrative sanction.



Mr. Carlo Rosa, pending the decision of the Court of Appeal, will comply with the disqualifying sanction above. In any case, the Board of Directors confirms that the governance system and delegation of powers adopted by the Company is suitable to guarantee the full business operation.

The Board of Directors, deeming that the Company acted in full compliance with the applicable regulations, unanimously renews its full trust in its Chief Executive Officer and its confidence in the prompt and successful outcome of the proceedings before the proper Court.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it